Abstract
The human complement receptor type 1 (CR1, C3 b/C4b receptor) is a polymorphic membrane glycoprotein expressed on human erythrocytes, peripheral leukocytes, plasma and renal glomerular podocytes, which consists of transmembrane and cytoplasmic domains with 30 repeating homologous protein domains knows as short consensus repeats (SCR). CR1 has been used as an inhibitor for inflammatory and immune system for the past several years. Recently, it is reported that CR1 was found to suppress the hyper-acute rejection in xeno-transplantation and can be used to cure autoimmune diseases. A soluble form of CR1, called sCR1, is a recombinant CR1 by cleaving the transmembrane domain at C-terminus and has been expressed in Chinese Hamster Ovary (CHO) cells. Several purification methods for sCR1 from CHO cells have been reported, but most of them require complicated steps at high cost. Moreover, such methods are mostly performed under the pH condition apt to denaturing sCR1 and causes sCR1 losing its activity. We here report a rapid and efficient method to purify sCR1 from CHO cell. The new method consists of a two-stage of cell culture by cultivating cells in serum medium followed by serum-free medium, and a two-stage of column purification by means of heparin and gel filtration column chromatography. By using this novel method, sCR1 can be purified in a simple and effective way with high yield and purity. Furthermore, the purified sCR1 was confirmed to retain its activity to suppress the complement activationin vivo andex vivo.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Klickstein, L. B., W. W. Wong, J. A. Smith, J. H. Weis, J. G. Wilson, and D. T. Fearon (1987) Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins.J. Exp. Med. 165: 1095–1112.
Klickstein, L. B., Bartow T. J., V. Miletic, L. D. Rabson, J. A. Smith, and D. T. Fearon (1988) Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.J. Exp. Med. 168: 1699–1717.
Hourcade, D., D. R. Miesner, J. P. Atkinson, and V. M. Holers (1988) Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1.J. Exp. Med. 168: 1255–1270.
Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Jr. Marsh, G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon (1990) Soluble human complement receptor type 1:in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.Science 249: 146–151.
Yeh, C. G., H. C. Jr. Marssh, G. R. Carson, L. Berman, M. F. Concino, S. M. Scesney, R. E. Kuestner, R. Skibbens, K. A. Donahue, and S. H. Ip (1991) Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats.J. Immunol. 146: 250–256.
Mulligan, M. S., C. G. Yeh, A. R. Rudolph, and P. A. Ward (1992) Protective effects of soluble CR1 in complement-and neutrophil-mediated tissue injury.J. Immunol. 148: 1479–1485.
Pruitt, S. K., A. D. Kirk, R. R. Bollinger, H. C. Jr. Marsh, B. H. Collins, J. L. Levin, J. R. Mault, J. S. Heinle, S. Ibrahim, A. R. Rudolph (1994) The effect of soluble complement receptor type 1 on hyper-acute rejection of porcine, xenografts.Transplanation 57: 363–370.
Jung, S., K. V. Toyka, and H. P. Hartung (1995) Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats.Neurosci Lett. 200: 167–70.
Piddlesden, S. J., S. Jiang, J. L. Levin, A. Vincent, and B. P. Morgan (1996) Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis.J. Neuroimmunol. 71: 173–177.
Mikata, S., S. Miyagawa, M. Yoshitatsu, M. Ikawa, M. Okabe, H. Matsuda, and R. Shirakura (1998) Prevention of hyperacute rejection by phosphatidylinositol- anchored mini-complement receptor type 1.Transpl. Immunol. 6: 107–110
Scesney, S. M., S. C. Makrides, M. L. Gosselin, P. J. Ford, B. M. Andrews, E. G. Hayman, and H. C. Jr. Marsh (1996) A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway.Eur. J. Immunol. 26: 1729–1735.
Rittershaus, C. W., L. J. Thomas, D. P. Miller, M. D. Picard, K. M. Geoghegan-Barek, S. M. Scesney, L. D. Henry, A. C. Sen, A. M. Bertino, G. Hannig, H. Adari, R. A. Mealey, M. L. Gosselin, M. Couto, E. G. Hayman, J. L. Levin, V. N. Reinhold, and H. C. Jr. Marsh (1999) Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules.J. Biol. Chem. 274: 11237–11244.
Wong, W. W., and S. A. Farrell (1991) Proposed structure of the F' allotype of human CR1. Loss of a C3b binding site may be associated with altered function.J. Immunol. 146: 656–662.
Seya, T., M. Matsumoto, M. Hatanaka, M. Okada, T. Masaki, and K. Iida (1996) Rapid purification of human complement receptor type 1 (CD35, CR1).J. Biochem. Biophys. Methods. 32: 69–76.
Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature 227: 680–685
Dykman, T. R., J. A. Hatch, M. S. Aqua, and J. P. Atkinson (1985) Polymorphism of the C3b/C4b receptor (CR1): characterization of a fourth allele.J. Immunol. 134: 1787–1789.
Carron, J. A., R. C. Bates, A. I. Smith, T. Tetoz, A. Arellano, D. L. Gordon, and G. F. Burns (1996) Factor H copurifies with thrombospondin isolated from platelet secretate.Biochim. Biophys. Acta 1289: 305–311.
Honda, J., H. Andou, T. Mannen, and S. Sugimoto (2000) Direct refolding of recombinant human growth differentiation factor 5 for large-scale production process.J. Biosci. Bioeng. 89: 582–589.
Birmingham, D. J., X. P. Shen, D. Hourcade, M. W. Nickells, and J. P. Atkinson (1994) Primary sequence of an alternatively spliced form of CR1. Candidate for the 75,000 M(r) complement receptor expressed, on chimpanzee erythrocytes.J. Immunol. 153: 691–700.
Nickells, M., R. Hauhart, M. Krych, V. B. Subramanian, K. Geoghegan-Barek, H. C. Jr. Marsh., and J. P. Atkinson (1998) Mapping epitopes for 20 monoclonal antibodies to CR1.Clin. Exp. Immunol. 112: 27–33.
Hack, C. E., J. Paardekooper, and F. Van Milligen (1990) Demonstration in human plasma of a form of C3 that has the conformation of “C3b-like C3”.J. Immunol. 144: 4249–4255.
Seya, T., M. Okada, K. Hazeki and S. Nagasawa (1991) Regulatory system of guinea-pig complement C3b: tests for compatibility of guinea-pig factors H and I with human factors.Mol. Immunol. 28: 375–382.
Mevorach, D., J. O. Mascarenhas, D. Gershov, and K. B. Elkon (1998) Complement-dependent clearance of apoptotic cells by human macrophages.J. Exp. Med. 188: 2313–2320.
Carrington, C. A., and G. dos Santos Cruz (2001) Effect of cell surface concentration of human DAF on transgenic pig aortic endothelial cells on the degree of protection afforded against human complement deposition.Xenotransplantation 8: 100–105.
Huang, J., D. Gou, C. Zhen, D. Jiang, X. Mao, W. Li, S. Chen, and C. Cai (2001) Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.FEMS Immunol. Med. Microbiol. 31: 203–209.
Umeda, M. (1991) Cultivation of mammalian cells in serum-free media.Hum. Cell. 4: 285–290.
Fukaya, K., S. Asahi, S. Nagamori, M. Sakaguchi, C. Gao, M. Miyazaki, and M. Namba (2001) Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV40 LT.In Vitro Cell Dev. Biol. Anim. 37: 266–269.
Jang, J. H., F. Wang, and M. Kan (1997) Heparan sulfate is required for interaction and activation of the epithelial cell fibroblast growth factor receptor-2IIIb with stromal-derived fibroblast growth factor-7.In Vitro Cell Dev. Biol. Anim. 33: 819–824.
Fujikawa, K., H. Suzuki, B. McMullen, and D. Chung (2001) Purification of human von Willebrand factorcleaving protease and its identification as a new member of the metalloproteinase family.Blood 98: 1662–1666.
Rosenberg, R. D., N. W. Shworak, J. Liu, and L. Zhang (1997) Heparan Sulfate Proteoglycans of the Cardiovascular System.J. Clin. Invest. 99: 2062–2070.
Kurumiya, Y., Y. Nimura, E. Takeuchi, K. Nozawa, M. Nagino, A. Hayata, A. Maeda, and S. Yoshida (1999) Active form of human hepatocyte growth factor is excreted into bile after hepatobiliary resection.J Hepatol 30: 22–28.
Garke, G., W. D. Deckwer, and F. B. Anspach (2000) Preparative two-step purification of recombinant human basic fibroblast growth factor from high-cell-density cultivation ofEscherichia coli.J. Chromatogr. B. Biomed. Sci. Appl. 737: 25–38.
Koyama, N., H. Ohmae, S. Tsuji, Y. Tanaka, T. Kurokawa, and O. Nishimura (2001) Improved preparation and crystallization of 25 kDa human fibroblast growth factor-9.Biotechnol. Appl. Biochem. 33: 117–121.
Seya, T., V. M. Holers, and J. P. Atkinson (1985) Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).J. Immunol. 135: 2661–2667.
Moen, O., K. Hogasen, E. Fosse, E. Dregelid, V. Brockmeier, P. Venge, M. Harboe, and T. E. Mollnes (1997) Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass.Ann. Thorac. Surg. 63: 105–111.
Saito, N., S. Motoyama, and J. Sawamoto (2000) Effects of new polymer-coated extracorporeal circuits on biocompatibility during cardiopulmonary bypass.Artif. Organs 24: 547–554.
Skerl, K. G., R. A. Calderone, T. Sreevalsan, J. Burge, A. Nicholson-Weller, and K. F. Austen (1981) Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase.J. Immunol. 126: 232–235.
Kaidoh, T., S. Natsuume-Sakai, and M. Takahashi (1981) Murine C4-binding protein: a rapid purification method by affinity chromatography.J. Immunol. 126: 463–467.
Ram, S., M. Cullinane, A. M. Blom, S. Gulati, D. P. McQuillen, R. Boden, B. G. Monks, C. O'Connell, C. Elkins, M. K. Pangburn, B. Dahlback, and P. A. Rice (2001) C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae.Int. Immunopharmacol. 1: 423–432.
Carron, J. A., R. C. Bates, A. I. Smith, T. Tetoz, A. Arellano, D. L. Gordon, and G. F. Burns (1996) Factor H copurifies with thrombospondin isolated from platelet secretate.Biochim. Biophys. Acta 1289: 305–311.
Scott, P. E., D. B. Purkall, and S. Ruddy (1997) Effects of thrombospondin purified by heparin affinity or ionexchange chromatography on the alternative complement pathway.J. Immunol. Methods. 202: 213–216.
Henry, S. P., P. C. Giclas, J. Leeds, M. Pangburn., C. Auletta, A. A. Levin, and D. J. Kornbrust (1997) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.J. Pharmacol. Exp. Ther. 281: 810–816.
Lopez-Trascasa, M., D. H. Bing, M. Rivard, and A. Nicholson-Weller (1989) Factor J: Isolation and characterization of a new polypeptide inhibitor of complement C1.J. Biol. Chem. 264: 16214–16221.
Diamond, M. S., R. Alon, C. A. Parkos, M. T. Quinn, and T. A. Springer (1995) Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1).J. Cell Biol. 130: 1473–1482.
Peter, K., M. Schwarz, C. Conradt, T. Nordt, M. Moser, W. Kubler, and C. Bode (1999) Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18).Circulation. 100: 1533–1539.
Sinitsyn, V. V., E. T. Bokchubaev, A. G. Mamontova, N. V. Ovtrakht, E. L. Nasonov, G. A. Konovalov, and V. V. Kukharchuk (1992) C3a and C5a anaphylatoxins bind to heparin-based sorbent in low density lipoprotein apheresis:in vitro andin vivo investigations.Artif. Organs. 16: 291–293.
Lidington, E. A., D. O. Haskard, and J. C. Mason (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury.Blood 96: 2784–2792.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kato, H., Inoue, T., Ishii, N. et al. A novel simple method to purify recombinant soluble human complement receptor type 1 (sCR1) from CHO cell culture. Biotechnol. Bioprocess Eng. 7, 67–75 (2002). https://doi.org/10.1007/BF02935882
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02935882